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Purpose: Whether bevacizumab enhances the effect of the epider-
mal growth factor receptor (EGFR) inhibitor gefitinib on EGFR 
mutant non–small cell lung cancers (NSCLCs) remains unknown. 
We conducted a phase II trial to investigate the efficacy and safety 
of gefitinib when combined with bevacizumab as first-line therapy 
in patients with advanced NSCLC harboring EGFR gene mutations.
Methods: In this trial, 42 patients with a performance status of 0 to 
2 received gefitinib (250 mg/d) and bevacizumab (15 mg/kg, every 3 
weeks). The primary end point of this study was the 1-year progres-
sion-free survival (PFS) rate. We assumed that a 1-year PFS rate of 
55% would indicate potential usefulness and that a 1-year PFS rate 
of 40% would constitute the lower limit of interest.
Results: Forty-two patients were enrolled in the study with a median 
age of 73 (range 42–86) years. Activating EGFR gene mutations 
included exon 19 deletion (57%) and L858R point mutations in exon 
21 (38%). The objective response rate was 73.8% and included two 
complete responses. The 1-year PFS rate and median PFS time were 
56.7% (95% confidence interval [CI] 39.9–70.5) and 14.4 months 
(95% CI 10.1–19.2), respectively. The median PFS differed signifi-
cantly between EGFR exon 19 deletion and the L858R point muta-
tion (18.0 versus 9.4 months, respectively; p = 0.006). The median 
overall survival had not yet been reached. Severe adverse events 
included grade 3 skin rash (15%), hypertension (17%), aspartate 
transaminase/alanine aminotransferase elevation (17%), proteinuria 
(7%), intracranial hemorrhage (2%), and grade 4 perforation of the 
digestive tract (2%). There were no treatment-related deaths.
Conclusion: Gefitinib in combination with bevacizumab as first-
line therapy seems to be a favorable and well-tolerated treatment 
for patients with advanced NSCLC with activating EGFR gene 
mutations, especially those with EGFR exon 19 deletion mutations, 
although the primary end point was not met because the lower limit 
of the CI was less than 40%.
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(J Thorac Oncol. 2015;10: 486–491)
The discovery of epidermal growth factor receptor (EGFR) mutations in relation to EGFR tyrosine kinase inhibitors 
(TKIs) occurred in the dawn of the era of molecular target-
ing therapy for non–small cell lung cancer (NSCLC) and has 
significantly influenced its treatment.1,2 Dramatic responses 
to EGFR-TKIs, such as gefitinib and erlotinib, have been 
observed in patients with NSCLC. Several phase III tri-
als have shown beneficial effects of EGFR-TKIs in patients 
with NSCLC with EGFR mutations, and EGFR-TKIs have 
become indispensable therapeutic agents for patients with 
EGFR mutant NSCLC.3–6 However, almost all patients who 
initially respond to EGFR-TKIs inevitably develop resistance 
in approximately 10 months.
Vascular endothelial growth factor (VEGF) is another 
target of NSCLC therapy. VEGF-A, by binding to VEGF 
receptor (VEGFR)-2, promotes angiogenesis in the tumor 
microenvironment and indirectly promotes tumor growth. 
Bevacizumab, a recombinant monoclonal antibody target-
ing VEGF-A, improves progression-free survival (PFS) and 
overall survival (OS) in patients with advanced NSCLC when 
combined with cytotoxic chemotherapy consisting of carbo-
platin and paclitaxel.7
Dual inhibition of EGFR and VEGFR signaling is 
a promising strategy for the following reasons: (1) EGFR 
influences VEGFR signaling (e.g., EGFR signal activation 
increases VEGF production)8–11; and (2) anti-EGFR therapy 
targets cancer cells, whereas anti-VEGF therapy mainly tar-
gets tumor vascular endothelial cells; and (3) the adverse-
effect profile of EGFR-TKIs is completely different from that 
of bevacizumab. A number of preclinical studies have shown 
the efficacy of EGFR/VEGFR dual inhibition in many cancer 
types.12–15 We also showed in a xenograft model that vande-
tanib, a dual inhibitor of EGFR and VEGFR, or combination 
therapy using gefitinib and bevacizumab inhibited EGFR 
mutant tumors more effectively compared with gefitinib 
monotherapy.16 Nevertheless, it has not been well examined 
clinically whether combination therapy targeting both EGFR 
and VEGFR signaling has a synergic effect in the treatment of 
EGFR mutant NSCLC.
For the above reasons, we planned a phase II trial 
evaluating gefitinib in combination with bevacizumab as 
the first-line therapy for advanced NSCLC with activating 
EGFR gene mutations. The aim of this trial was to evalu-
ate the efficacy and toxicity of gefitinib plus bevacizumab 
combination therapy and then to assess whether this strategy 
should be further evaluated in patients with EGFR mutant 
NSCLC in a phase III trial.
PATIENTS AND METHODS
The study was conducted by the Okayama Lung Cancer 
Study Group, a community-based cooperative group. The pro-
tocol was approved by the institutional review boards and/or 
an ethics committee.
Eligibility Criteria
Patients were enrolled at 11 institutes in Japan. The eligi-
bility criteria of this study were as follows: age greater than 20 
years, pathologically proven as patient with NSCLC, stage IIIB/
IV disease (6th edition of the tumor, node, metastasis tumor, 
node, metastasis staging system of the International Union 
against Cancer) or postoperative recurrence, measurable tumor 
sites, Eastern Cooperative Oncology Group performance status 
of 0 to 2, tumors with EGFR mutations other than the exon 
20 T790M mutation, no prior systemic therapy except for post-
operative adjuvant cytotoxic chemotherapy more than 1 year 
before registration, appropriate organ function, and acquisition 
of written informed consent. Baseline pretreatment evaluations 
included a complete history, physical examination, laboratory 
tests, a chest radiograph, a computed tomography (CT) scan of 
the chest and abdomen, and a radionuclide bone scan or posi-
tron emission tomography/CT. The baseline CT scan should 
have been done within 4 weeks before registration. Exclusion 
criteria were as follows: potential for curative treatment, history 
of massive hemoptysis, cavity-forming lesion or tumor invading 
major blood vessels, uncontrolled hypertension, radiographic 
signs of interstitial lung disease, symptomatic brain metastasis, 
pleural effusion or pericardial effusion requiring drainage, seri-
ous and uncontrollable concomitant systemic disorder (includ-
ing heart disease, infection, and diabetes mellitus), history of 
drug allergy, and lactation/pregnancy.
Detection of EGFR Gene Mutations
EGFR gene mutation status was assessed by direct 
sequencing, the polymerase chain reaction clamp method,17 
or the Scorpion Amplified Refractory Mutation System meth-
ods,18 all of which have been approved in Japan.
Treatment
Gefitinib was administered orally at 250 mg/d, starting 
on the first day of the treatment protocol. Bevacizumab was 
administered intravenously at 15 mg/kg on the first day of 
the treatment protocol and was repeated at 3-week intervals. 
Therapy was continued until disease progression or unaccept-
able toxicity from the treatment.
Assessments of Toxicity and Antitumor Activity
All toxicities were graded according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events v4.0. The standard Response Evaluation Criteria in 
Solid Tumors (version 1.1) were used to evaluate responses. 
The CT scan to assess target or nontarget lesions was designed 
to be done every 4 weeks until the response was confirmed. 
After confirmation of the response, CT scans were done every 
12 weeks. Complete and partial responses were confirmed not 
less than 4 weeks apart. Stable disease required disease stabi-
lization for at least 6 weeks. Treatment response and PFS were 
assessed by the investigators.
Treatment was discontinued if patients developed 
pneumonitis, intracranial hemorrhage, or gastrointestinal 
perforation (any grades); grade 4 vomiting; or other nonhe-
matologic toxicity of grade ≥3 other than thromboembolic 
events, hypertension, and proteinuria. In cases of grade 3/4 
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thromboembolic events, grade 4 hypertension, or grade 3 
proteinuria with nephrotic syndrome, gefitinib could be con-
tinued without bevacizumab. If patients developed grade 3 
nausea/vomiting or other nonhematologic toxicities of grade 
2 other than nausea/vomiting, thromboembolic events, hyper-
tension, or proteinuria, both bevacizumab and gefitinib were 
postponed until recovery to grade 1.
Statistical Considerations
The primary end point of this study was 1-year PFS rate. 
Secondary end points included median PFS, OS, objective 
response rate (RR), and toxicity. We decided to use a 1-year 
PFS rate for gefitinib of 40% from the previous clinical trial 
data3 and assumed a 15% increase in the 1-year PFS rate as 
potentially useful, because bevacizumab increased the 1-year 
PFS rate by approximately 15% when combined with carbo-
platin/paclitaxel (E4599 trial).7 Based on this knowledge, we 
assumed that a 1-year PFS rate of 55% would indicate potential 
usefulness and that a 1-year PFS rate of 40% would constitute 
the lower limit of interest, with α = 0.05 and β = 0.2. The esti-
mated number of patients needed was 40. Assuming dropout 
of two patients, 42 patients were required. PFS in this study 
was defined as the interval between the date of enrollment and 
the date of the first observation of disease progression or death 
from any cause. OS was defined as the interval between the date 
of enrollment and the date of death or the last follow-up visit. 
All statistical analyses were conducted using STATA (ver. 12.1; 
StataCorp, College Station, TX). The survival distribution was 
estimated using the Kaplan–Meier method. An interim analysis 
was not planned. All p values corresponded to two-sided tests, 
and significance was set at p less than 0.05.
RESULTS
Patient Characteristics
Between October 2010 and April 2012, 42 patients were 
enrolled in this study (Table 1). The median age was 73 years 
(ranged 42–86), and 60% of the patients were female (25 of 
42). The majority of patients were never smokers (81%, 34 of 
42), had a good performance status (0–1; 95%, 40 of 42), and 
showed an adenocarcinoma histology (95%, 40 of 42). Thirty-
three patients (79%) had stage IV disease, and nine (21%) 
had postoperative relapse. Activating EGFR gene mutations 
in the patients included exon 19 deletion (57%, 24 of 42) and 
an exon 21 point mutation (L858R: 38%, 16 of 42). Of the 
remaining two patients, one had an exon 18 G719A mutation 
and the other had an exon 21 L861Q mutation.
Treatment Delivery
The median duration of gefitinib treatment was 13.6 
(range 0.8–37.6) months. Gefitinib was interrupted in 11 
patients (26%) because of adverse events (liver dysfunction 
in seven patients, general fatigue in two, infection in one, and 
development of concurrent disease in one). The median inter-
ruption duration was 25 (range 12–42) days. Bevacizumab was 
administered for a median of nine (range 0–33) times. At the 
time of the study analysis, treatment was discontinued in 34 
patients (81%) because of disease progression (18 patients), 
adverse events (10 patients: liver dysfunction in six , pneumo-
nitis in two, intracranial hemorrhage in one , and intestinal per-
foration in one), or patient rejection (four patients). One patient 
received gefitinib without bevacizumab because of the develop-
ment of renal failure of unknown causes after registration.
Response and Survival
In an intention-to-treat analysis, the RR was 73.8% (31 
of 42, 95% confidence interval [CI] 58.0–86.1) with two com-
plete responses (Table 2). The disease control rate, defined as 
the percentage of patients with a complete response, a partial 
response, or stable disease, was 97.6% (95% CI 87.4–99.9; 
Table 2). At the time of the survival analysis, with a median 
follow-up time of 25.1 months, 29 patients (69%) had experi-
enced disease progression or died. The median 1-year PFS rate 
was 56.7% (95% CI 39.9–70.5). This did not meet the primary 
end point because the lower limit of the CI was less than 40%. 
The median PFS time was 14.4 months (95% CI 10.1–19.2; 
Fig. 1A). In a subanalysis based on the EGFR mutation status, 
there was a significant difference in PFS between the EGFR 
exon 19 deletion and exon 21 L858R mutations (18.0 versus 
9.4 months, respectively; p = 0.006; Fig. 1B). The median OS 
was not reached at the time of analysis (Fig. 2).
Toxicity
We assessed toxicity in 41 patients (the patient who did 
not receive bevacizumab was not included in the analysis). 
TABLE 1.  Patient Characteristics
Median age, years (range) 73 (42–86)
Gender (female/male) 25/17
Smoking (never/former/current) 34/8/0
ECOG PS (0–1/2) 40/2
Histology (Ad/unclassified NSCLC) 40/2
Stage (IV/postoperative relapse) 33/9
EGFR mutation status
(del/L858R/others) 24/16/2
ECOG, Eastern Cooperative Oncology Group; PS, performance status; Ad, 
adenocarcinoma; NSCLC, non–small-cell lung cancer; del, exon 19 deletion mutation; 
L858R, exon 21 L858R point mutation.
TABLE 2.  Response Rate and Disease Control Rate
No. of Patients %
Response
  Complete response 2 4.7
  Partial response 29 69.0
 Stable disease 10 23.8
 Progressive disease 0 0
 Not evaluable 1 2.4
Response rate (95% CI) 31 73.8 (58.0–86.1)
Disease control rate (95% CI) 41 97.6 (87.4–99.9)
Disease control comprises partial responses, complete responses, and stable disease.
CI, confidence interval.
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The adverse events in this study are listed in Table 3. The most 
common adverse event was skin rash (93%, 38 of 41). In 24 of 
these 38 cases, the skin rash was of grade 1. The second most 
common adverse event was hypertension (68%, 28 of 41). 
Both adverse events were managed effectively using either 
an appropriate treatment or interruption/dose reduction of the 
study treatment without any treatment discontinuation. Other 
common adverse events were proteinuria, diarrhea, and aspar-
tate transaminase/alanine aminotransferase elevation, all of 
which are known adverse events of gefitinib or bevacizumab 
monotherapy. One patient developed grade 4 colonic perfo-
ration on day 10. The patient underwent abdominal surgery 
and recovered. There was no bowel metastasis, but the patient 
regularly took a nonsteroidal anti-inflammatory drug for the 
pain caused by the bone metastasis. This might have caused 
the colonic perforation. Another patient developed grade 3 
intracranial hemorrhage on day 119, without any brain metas-
tasis at the beginning of treatment or at the time of intracranial 
hemorrhage.
Subsequent Treatments
Thirty-four of the 42 patients discontinued the protocol 
treatment at the time of the analysis. We evaluated the subse-
quent treatments among the 34 patients (Table 4). Eighteen 
patients received platinum-based doublet chemotherapy 
(53%), and four patients received single-agent chemotherapy 
(12%). Nine patients received erlotinib or readministration of 
gefitinib (26%).
DISCUSSION
We conducted a prospective biomarker study to evalu-
ate combination therapy with the EGFR-TKI gefitinib and the 
anti-VEGF antibody bevacizumab in treatment-naive patients 
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FIGURE 1. A. Progression-free survival (PFS) curve for the 
42 patients. B. PFS curves according to epidermal growth 
factor receptor (EGFR) mutation status. Solid line, EGFR exon 
19 deletion; dashed line, exon 21 L858R mutation. Gray lines 
represent 95% confidence intervals.
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FIGURE 2.  Overall survival curve for the 42 patients. Gray 
lines represent 95% confidence intervals.
TABLE 3.  Adverse Events
Toxicity
Grade
No. of Patients
Any Grade 3 4
Rash 38 (93%) 6 (15%) 0
Hypertension 28 (68%) 7 (17%) 0
Proteinuria 23 (56%) 3 (7%) 0
Diarrhea 19 (46%) 1 (2%) 0
Aspartate transaminase/alanine 
aminotransferase increase
11 (27%) 7 (17%) 0
Nausea/vomiting 4 (10%) 0 0
Pneumonitis 3 (7%) 0 0
Colonic perforation 1 (2%) 0 1 (2%)
Intracranial hemorrhage 1 (2%) 1 (2%) 0
TABLE 4.  Subsequent Treatments
Platinum-based doublet chemotherapy 18 (53%)
Single-agent chemotherapy 4 (12%)
EGFR-TKI treatment 9 (26%)
Best supportive care 3 (9%)
Total 34 (100%)
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor.
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with EGFR mutant NSCLC. In this study, we found a 1-year 
PFS rate of 56.7%, a median PFS time of 14.4 months, and 
an RR of 73.8%.
EGFR-TKIs, such as gefitinib and erlotinib, are among 
the first choices for the treatment of EGFR mutant NSCLC, 
but the effects last only approximately 10 months because 
of acquired resistance. Therefore, developing a new strategy 
improved over EGFR-TKI monotherapy is an urgent issue. 
In our study, PFS was 4 to 5 months longer with bevaci-
zumab plus gefitinib compared with historical control EGFR-
TKI monotherapy.3–6 In a previous phase III trial comparing 
erlotinib plus bevacizumab with erlotinib plus placebo in 
unselected patients with NSCLC (the BeTa trial), the addition 
of bevacizumab to erlotinib therapy showed no improvement 
in OS (9.3 versus 9.2 months, respectively) and only a slight 
improvement in PFS (3.7 versus 1.7 months, respectively).19 
Although the data were not very impressive, erlotinib and 
bevacizumab combination treatment markedly prolonged PFS 
in the subgroup harboring EGFR mutations (17.1 versus 9.7 
months, respectively).19On the basis of this, a phase II clinical 
trial comparing bevacizumab plus erlotinib with erlotinib alone 
in EGFR mutant NSCLC was conducted, and it showed clini-
cal benefit of the combination therapy.20 In that study, PFS after 
bevacizumab and erlotinib combination therapy was approxi-
mately 6 months longer than that after erlotinib monotherapy 
(16.0 versus 9.7 months, respectively), consistent with our 
data. One of the possible mechanisms by which bevacizumab 
enhances the anticancer effect is through improved drug deliv-
ery to tumor tissues by normalizing tumor vessels. We recently 
reported data suggesting that increasing the dose intensity of 
gefitinib might lead to better outcomes for the treatment of 
EGFR mutant NSCLC.21,22 Bevacizumab, when combined 
with EGFR-TKIs, might increase intratumoral concentrations 
of EGFR-TKIs, leading to a better antitumor effect.
We also found that the PFS differed significantly 
according to the EGFR mutation type. Patients with EGFR 
exon 19 deletion mutations showed longer PFS than did those 
with exon 21 L858R mutations (18.0 versus 9.4 months, 
respectively; p = 0.006). A similar observation was made 
in the abovementioned study comparing bevacizumab plus 
erlotinib with erlotinib alone in patients with EGFR mutant 
NSCLC.19 Gefitinib, which is usually administered at one 
third of its maximum-tolerated dose, reportedly showed no 
difference in efficacy between EGFR exon 19 deletion and 
exon 21 L858R when used as a monotherapy (PFS; 9.0–11.5 
versus 9.6–10.8 months, respectively).3,4 However, erlotinib 
is administered at its maximum-tolerated dose and showed 
better efficacy in patients with the EGFR exon 19 deletion 
(11.0–15.3 versus 8.4–12.5 months, respectively).5,6 EGFR 
exon 19 deletion might be associated with a dose-dependent 
response to EGFR-TKIs, whereas exon 21 L858R might not. 
Actually, we revealed in a preclinical model that xenograft 
tumors harboring EGFR exon 19 deletion responded to gefi-
tinib in a dose-dependent manner.21 In this study, bevaci-
zumab might have increased the intratumoral concentration 
of gefitinib, leading to a better outcome in EGFR exon 19 
patients. In addition, it was reported that gefitinib or erlotinib 
has a higher affinity to EGFR exon 19 deletion than to EGFR 
exon 21 L858R.23,24 Taken together, these data might provide 
a biological explanation for the different outcomes between 
exon 19 deletion and exon 21 L858R.
The major adverse events included skin rash, diarrhea, 
proteinuria, and hypertension, all of which are known adverse 
events of gefitinib3,4 or bevacizumab.7 Skin rash of any grade 
was seen in 93% of patients in this study; grade >2 skin rash 
was seen in 15% of patients. For gefitinib monotherapy, the 
reported rates are 65% to 85% for skin rash of any grade and 
2% to 5% for grade >2 skin rash.3,4,25 Bevacizumab, when com-
bined with carboplatin and paclitaxel, was reported to show 
a higher incidence of grades 3 to 5 adverse events in elderly 
patients,26 and the current study included patients older (median 
age = 73 years) than historical controls (approximately 65 years 
of age).3,4 The cause might be the more frequent incidence of 
skin rash in this study. However, skin rash was also more fre-
quent with erlotinib plus bevacizumab combination therapy 
than with erlotinib monotherapy.19 Bevacizumab may exacer-
bate gefitinib-induced skin rash, although it is possible that the 
longer duration of the combination therapy might be a potential 
contributing factor. With regard to serious adverse events, there 
were three cases of pneumonitis (7%; one case of grade 1, two 
cases of grade 2), one case of intracranial hemorrhage (2%), 
and one case of perforation of the digestive tract (2%). The inci-
dent rate of pneumonitis during EGFR-TKI treatment, which 
is higher in Japanese patients, was equal to that in historical 
controls.3,4 Although all the patients with severe adverse events 
recovered, and no treatment-related death occurred, combina-
tion therapy with gefitinib plus bevacizumab seems to require 
more careful follow up compared with gefitinib monotherapy.
There are some limitations to the current study. Because 
this was a phase II single-arm trial, some selection bias 
was possible, and a simple comparison between our results 
and historical clinical data is inconclusive. In addition, we 
adapted three methods for EGFR mutation assessment (direct 
sequencing, the polymerase chain reaction clamp method, and 
the Scorpion Amplified Refractory Mutation System), all of 
which have different sensitivities. This might have caused 
some selection bias.
In conclusion, bevacizumab plus gefitinib combination 
therapy is a promising strategy for the treatment of EGFR 
mutant NSCLC with tolerable toxicity. Further studies inves-
tigating bevacizumab plus EGFR-TKI combination therapy in 
patients with EGFR mutant NSCLC are warranted.
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